Levodopa-induced	levodopa-induced	O	O	O	O
oromandibular	oromandibular	O	O	OTHERS	I
dystonia	dystonia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
progressive	progressive	O	O	OTHERS	I
supranuclear	supranuclear	O	O	OTHERS	I
palsy	palsy	O	O	OTHERS	I
.	.	O	O	O	O

Levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
have	have	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
in	in	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
and	and	O	O	O	O
multiple	multiple	O	DISEASE	OTHERS	I
system	system	O	DISEASE	OTHERS	I
atrophy	atrophy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Cranial	cranial	O	O	O	O
dystonias	dystonias	O	O	OTHERS	I
are	are	O	O	O	O
rare	rare	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
progressive	progressive	O	O	OTHERS	I
supranuclear	supranuclear	O	O	OTHERS	I
palsy	palsy	O	O	OTHERS	I
(	(	O	O	O	O
PSP	psp	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
report	report	O	O	O	O
we	we	O	O	O	O
describe	describe	O	O	O	O
an	an	O	O	O	O
unusual	unusual	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
reversible	reversible	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
Oromandibular	oromandibular	O	O	OTHERS	I
dystonia	dystonia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
OMD	omd	O	O	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
PSP	psp	O	O	OTHERS	I
patient	patient	O	O	O	O
to	to	O	O	O	O
highlight	highlight	O	O	O	O
the	the	O	O	O	O
importance	importance	O	O	O	O
of	of	O	O	O	O
recognizing	recognizing	O	O	O	O
this	this	O	O	O	O
drug	drug	O	O	O	O
related	related	O	O	O	O
complication	complication	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
PSP	psp	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
discuss	discuss	O	O	O	O
the	the	O	O	O	O
possible	possible	O	O	O	O
underlying	underlying	O	O	O	O
pathophysiology	pathophysiology	O	O	O	O
.	.	O	O	O	O

